INT70304

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 1996
Last Reported 2005
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 3.64
Pain Relevance 1.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il5) extracellular region (Il5)
Anatomy Link Frequency
sputum 1
monocytes 1
T lymphocytes 1
Il5 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 11 100.00 Very High Very High Very High
antagonist 1 99.72 Very High Very High Very High
abdominal pain 1 94.76 High High
aspirin 8 94.56 High High
cINOD 5 80.40 Quite High
cytokine 5 79.36 Quite High
chemokine 2 78.64 Quite High
Inflammatory response 1 68.48 Quite High
agonist 4 64.52 Quite High
corticosteroid 5 50.00 Quite Low
Disease Link Frequency Relevance Heat
INFLAMMATION 17 100.00 Very High Very High Very High
Pressure And Volume Under Development 3 100.00 Very High Very High Very High
Rhinitis 3 100.00 Very High Very High Very High
Peritonitis 2 99.80 Very High Very High Very High
Hypersensitivity 4 99.56 Very High Very High Very High
Asthma 11 98.68 Very High Very High Very High
Vomiting 2 96.04 Very High Very High Very High
Diarrhoea 1 95.32 Very High Very High Very High
Disease 5 95.24 Very High Very High Very High
Abdominal Pain 1 94.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A case of eosinophilic peritonitis in which ascites interleukin 5 presented at a high level.
Negative_regulation (ascites) of interleukin 5 associated with pressure and volume under development, rhinitis and peritonitis
1) Confidence 0.35 Published 2000 Journal Hepatogastroenterology Section Title Doc Link 11149008 Disease Relevance 1.04 Pain Relevance 0.09
Suplatast tosilate, which exerts its anti-inflammatory effect by suppressing IL-4 and IL-5 was given to patients with mild asthma for 6 weeks.
Negative_regulation (suppressing) of IL-5 associated with asthma and inflammation
2) Confidence 0.06 Published 1996 Journal Nihon Kyobu Shikkan Gakkai Zasshi Section Abstract Doc Link 9216184 Disease Relevance 0.79 Pain Relevance 0.27
Significant decreases in the percentage eosinophils and IL-5 level in induced sputum also occurred (P < 0.05).
Negative_regulation (decreases) of IL-5 in sputum
3) Confidence 0.04 Published 2005 Journal Respirology Section Body Doc Link 15823184 Disease Relevance 0.13 Pain Relevance 0
In this study, we provide evidence that NCX-4016 delivered to PMBC-derived T lymphocytes and monocytes causes a transitory inhibition of cell respiration and approximately 50% reduction of cellular ATP, which translates in a time-reversible inhibition of cell proliferation and IL-2, IL-4, IL-5, and IFN-gamma secretion.
Negative_regulation (inhibition) of IL-5 in monocytes
4) Confidence 0.02 Published 2004 Journal J. Immunol. Section Abstract Doc Link 15240674 Disease Relevance 0.07 Pain Relevance 0.28
In this study, we provide evidence that NCX-4016 delivered to PMBC-derived T lymphocytes and monocytes causes a transitory inhibition of cell respiration and approximately 50% reduction of cellular ATP, which translates in a time-reversible inhibition of cell proliferation and IL-2, IL-4, IL-5, and IFN-gamma secretion.
Negative_regulation (inhibition) of IL-5 in T lymphocytes
5) Confidence 0.01 Published 2004 Journal J. Immunol. Section Abstract Doc Link 15240674 Disease Relevance 0.07 Pain Relevance 0.28
Specific agents that are now in development for the treatment of allergic inflammation include inhibitors of eosinophilic inflammation (eg, anti-IL-5, CCR3 antagonists, and very late antigen 4 inhibitors), drugs that may inhibit allergen presentation, and inhibitors of T(H)2 cells.
Negative_regulation (inhibitors) of anti-IL-5 associated with rhinitis, inflammation, antagonist and hypersensitivity
6) Confidence 0.01 Published 2000 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 10887299 Disease Relevance 1.54 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox